- Define every component by sequence, modification, salt form and target amount before evaluating the finished blend.
- A single aggregate purity number cannot show that each peptide is present at its agreed quantity.
- Choose methods that distinguish components from each other and from relevant impurities in the actual blend matrix.
- Keep component-lot, blend-lot and packing links intact so a deviation can be investigated.
What should a peptide blend specification contain?
List each peptide separately with its sequence, terminal modifications, counter-ion or salt form and target quantity on an agreed basis. State whether the target is mass of supplied material, peptide content or a defined concentration in a finished matrix. These are not interchangeable numbers. A blend specification also needs total pack size, acceptable component ranges, mixing or fill homogeneity criteria where relevant, and the intended research context. If a component is replaced, the blend is no longer the same agreed composition.
A practical order file links component identity to the incoming lot and finished blend lot. The buyer should be able to trace the input quantity, release decision and output quantity without relying on a product nickname. ICH Q7 describes production and laboratory records for APIs [1]. It is a useful record-design reference, but research blends should not be presented as GMP APIs merely because the guide is cited.
- Each component's identity and specified form
- Amount or concentration basis per component
- Finished-pack target and acceptable ranges
- Component-lot to blend-lot reconciliation
Why is one HPLC purity figure insufficient for a blend?
A chromatogram reports what a specified method detects and separates. Two peptides can overlap, and an impurity can overlap a component. Detector response may differ between sequences, so an area percentage cannot be assumed to equal mass fraction for every component. The buyer needs to know which peak belongs to which peptide, whether the method resolves the relevant pairs, and how each component amount is calculated. A co-eluting impurity can make a tidy trace misleading.
ICH Q2(R2) asks whether an analytical procedure can identify or quantify an analyte in the presence of other components and recommends combined procedures when selectivity is insufficient [2]. For a blend, test selectivity against the finished mixture. LC-MS may help assign peaks, while a calibrated quantitative procedure addresses amount. The chosen methods and acceptance ranges must be written into the order specification.
The three separate reports
Ask for component identity evidence, a component-level quantitative result and an impurity or related-substances assessment. One method may contribute to more than one report, but its capability must be demonstrated for each intended result.
- Resolution of component peaks in the finished matrix
- Defined calibration or assay basis for each component
- Lot-linked chromatograms and mass evidence
- Named reporting threshold and unresolved-peak policy
How should blend homogeneity and changes be handled?
A result from one sampled container may not represent every pack if the blend is divided or filled across a run. Define where samples are taken and how many containers or positions are assessed according to project risk. Record the mixing and filling sequence, sample identifiers and acceptance decision. A simple blend may need only a targeted check; a complex formulation may require method development before any homogeneity claim is supportable.
Repeat orders should use the same component definitions and an agreed comparison rule. Changes in component source, counter-ion, ratio, analytical method or primary pack can affect results even when the commercial blend name stays unchanged. ICH Q14 treats analytical procedure changes as a lifecycle issue [3]. A research buyer can use that principle to ask for a bridged method and representative comparison, without claiming regulatory validation that has not been performed.
- Document sampling positions or containers
- Retain component and blend lot references
- Specify what triggers requalification
- Compare representative samples after a material or method change
This article is for laboratory, analytical, procurement and qualified cosmetic-science contexts. It is not medical advice and does not provide dosing, administration or personal-use instructions.
Frequently asked questions
Can a peptide blend COA list only total purity?+
Total purity alone does not establish each component's identity or amount. Request component-specific results and method context when the formulation ratio matters.
Does LC-MS provide the amount of every peptide in a blend?+
LC-MS can support identification. Quantitative results require a suitable calibrated method and assessment of matrix effects and component response; mass detection alone is not a complete assay.
Should the component lot numbers appear in the finished blend record?+
Yes. The blend-lot record should retain a traceable link to each input lot and the quantity used so a complaint or deviation can be investigated.
Are these testing rules universal for all blends?+
No. The analytical plan depends on the sequences, matrix, concentration, intended research use and agreed risk level. The buyer and laboratory should approve it before release.